November 27, 2007Diabetes Care
Management of Type 2 Diabetes in Treatment-Naive Elderly Patients
Key result
Vildagliptin monotherapy reduced A1C by 1.2% in older patients (≥65 years) compared to 1.0% in younger patients (<65 years) with type 2 diabetes (P=0.092).
Why the study?
Does vildagliptin monotherapy improve glycemic control and is it safe in treatment-naive elderly patients with type 2 diabetes?
Population
Treatment-naive patients with type 2 diabetes, pooled from multiple trials. Efficacy cohort: n=1,469. Safety…
Comparison
Vildagliptin monotherapy 100 mg daily for 24 weeks vs Placebo or active comparator
Design
Meta-analysis, randomized, double-blind
Follow-up
24 weeks for efficacy, >=12 weeks for safety
Authors
Discussion
Loading...
Member takes
Implication
Supports vildagliptin monotherapy in treatment-naive elderly; confirms comparable A1C efficacy versus younger adults.
Study Design
Type
Meta-Analysis (n=1,469)
Blinding
Double-blind
Randomization
Randomized
Structured PICO
Does vildagliptin monotherapy improve glycemic control and is it safe in treatment-naive elderly patients with type 2 diabetes?
P
Population
1,469 treatment-naive patients with type 2 diabetes analyzed to compare the efficacy of 24-week vildagliptin monotherapy between older (≥65 years) and younger (<65 years) patients.
I
Intervention
Vildagliptin monotherapy 100 mg daily for 24 weeks
C
Comparator
Placebo or active comparator
O
Outcome
Change from baseline in A1C and fasting plasma glucose (FPG) at 24 weekssurrogate
Main Result
Absolute Event Rate: -1.2% vs -1%
p-value: p=0.092
Vildagliptin monotherapy provides effective glycemic control with a low risk of hypoglycemia and weight loss in treatment-naive elderly patients with type 2 diabetes.
Cite This Study
Pratley et al. (2007) conducted a meta-analysis in Type 2 diabetes (n=1,469). Vildagliptin vs. Younger patients (<65 years) was evaluated on Adjusted mean change from baseline in A1C (p=0.092). Vildagliptin monotherapy reduced A1C by 1.2% in older patients (≥65 years) compared to 1.0% in younger patients (<65 years) with type 2 diabetes (P=0.092).